In 2014 Almirall divested its respiratory franchise to Astrazeneca, focusing on dermatology, and has pursued strategic acquisitions to expand its dermatology portfolio. Almirall operates a global network with over 1,800 employees, 15 subsidiaries, and distribution in over 100 countries across 5 continents. The company is leveraging AI-driven innovation in drug discovery to strengthen its competitive position in the dermatology space.
Cyborg Score Rationale
Almirall demonstrates solid fundamentals as Europe's leading medical dermatology company with €900M+ revenue, consistent growth, and a disciplined strategy. The company is actively investing in innovation partnerships (AI drug discovery with Absci) and maintaining a robust pipeline of novel therapeutics, though execution risks remain in a competitive global pharma landscape.
Top Insights
The company is the leading European company in medical dermatology with an expanding biologics portfolio and a robust pipeline of novel therapeutics.
Almirall and Absci announced expansion of their AI Drug Discovery collaboration with a second dermatology target, combining Absci's Integrated Drug Creation platform with Almirall's dermatology expertise.
Almirall continued to deliver strong sales growth in the first quarter of 2025, in line with expectations and longer-term growth trajectory.
The company specializes in medical dermatology and develops innovative treatments for diseases including psoriasis, atopic dermatitis, actinic keratosis, and acne.
Named Competitors
Dupilumab — Leading biologic for atopic dermatitis
Skyrizi — Risankizumab for psoriasis
Opsumit — Pulmonary hypertension and dermatology treatments
Dermatological Portfolio — European dermatology specialist
Recent Developments
(August 2025) Expanded AI drug discovery collaboration with Absci, selecting second dermatology target
(May 2025) Q1 2025 results showed strong sales growth in line with longer-term trajectory
(Ongoing) Leadership transition with Carlos Gallardo Piqué assuming CEO role in 2022
Open the full interactive Almirall, S.A. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.